On this site you will find clinical studies with cannabis or single
cannabinoids in different diseases and case reports on the use of cannabis by
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.
|Title||[The therapeutic use of delta-9-tetrahydrocannabinol (dronabinol) in refractory neuropathic pain] [Article in French].|
|Author(s)||Clermont-Gnamien S, Atlani S, Attal N, Le Mercier F, Guirimand F, Brasseur L.|
|Journal, Volume, Issue||Presse Med 2002;31(39 Pt 1):1840-5.|
|Major outcome(s)||No signficant effect of THC on pain|
INTRODUCTION: Despite the recent discovery of the potential mechanisms underlying the analgesic effects of cannabis, few clinical studies have so far assessed its analgesic effects, notably in the treatment of chronic non-malignant pain. All the studies used administration of cannabis alone. The aim of this open, pilot, study was to assess the efficacy and side effect profile of oral dronabinol (tetrahydrocannabinol - THC) in the treatment of refractory neuropathic pain.METHODS: Seven patients (3 women/4 men), aged 60 +/- 14 years, suffering from chronic refractory neuropathic pain, received oral THC titrated to the maximum dose of 25 mg/day (mean dose: 15 +/- 6 mg), during an average of 55,4 days (range: 13-128). Various components of pain (continuous, paroxysmal and brush-induced allodynia) were assessed using VAS scores. Health-related Quality of Life (HRQL) was evaluated using the Brief Pain Inventory, and the Hospital Anxiety and Depression scale was used to measure depression and anxiety.RESULTS: THC did not induce significant effect on the various pain, HRQL and anxiety and depression scores. Numerous side effects (notably sedation and asthenia) were observed in 5 patients out of 7, requiring premature discontinuation of the drug in 3 patients.CONCLUSION: The present study did not reveal any significant efficacy of THC in a small cohort of patients with chronic refractory neuropathic pain, but underlined the unfavorable side effect profile of the drug. These results may partly relate to the fact that oral dronabinol exhibits a poor therapeutic ratio (efficacy at the price of side effects). The development of new and better tolerated cannabinoids is warranted.
|Dose(s)||Maximum dose of 25 mg/day (mean: 15 mg)|
|Duration (days)||average of 55,4 days|
|Participants||7 patients with neuropathic pain|
|Type of publication||Medical journal|
|Address of author(s)||Service de pharmacie, Hopital Ambroise Pare, Boulogne, France. firstname.lastname@example.org|